Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study

Manfredi Rizzo, Ali A. Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano, Stefano Genovese, Antonio Ceriello

Research output: Contribution to journalArticle

Abstract

Background: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods: We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter. Results: There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months. Conclusions: Liraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.

Original languageEnglish
Article number162
JournalCardiovascular Diabetology
Volume15
Issue number1
DOIs
Publication statusPublished - Dec 3 2016

Fingerprint

Carotid Intima-Media Thickness
Prospective Studies
Metformin
Fasting
National Heart, Lung, and Blood Institute (U.S.)
Incretins
Glucagon-Like Peptide 1
Waist Circumference
Liraglutide
LDL Cholesterol
Type 2 Diabetes Mellitus
Triglycerides
Body Mass Index
Body Weight
Blood Pressure
Inflammation
Lipids

Keywords

  • Cardiovascular risk
  • Carotid intima-media thickness
  • Liraglutide
  • Metabolic syndrome

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome : An 18-month prospective study. / Rizzo, Manfredi; Rizvi, Ali A.; Patti, Angelo Maria; Nikolic, Dragana; Giglio, Rosaria Vincenza; Castellino, Giuseppa; Li Volti, Giovanni; Caprio, Massimiliano; Montalto, Giuseppe; Provenzano, Vincenzo; Genovese, Stefano; Ceriello, Antonio.

In: Cardiovascular Diabetology, Vol. 15, No. 1, 162, 03.12.2016.

Research output: Contribution to journalArticle

Rizzo, Manfredi ; Rizvi, Ali A. ; Patti, Angelo Maria ; Nikolic, Dragana ; Giglio, Rosaria Vincenza ; Castellino, Giuseppa ; Li Volti, Giovanni ; Caprio, Massimiliano ; Montalto, Giuseppe ; Provenzano, Vincenzo ; Genovese, Stefano ; Ceriello, Antonio. / Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome : An 18-month prospective study. In: Cardiovascular Diabetology. 2016 ; Vol. 15, No. 1.
@article{6d4abc667896485e925158b5b460395b,
title = "Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study",
abstract = "Background: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods: We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were na{\"i}ve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter. Results: There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26{\%} of subjects no longer fulfilled the criteria for the MetS after 18 months. Conclusions: Liraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.",
keywords = "Cardiovascular risk, Carotid intima-media thickness, Liraglutide, Metabolic syndrome",
author = "Manfredi Rizzo and Rizvi, {Ali A.} and Patti, {Angelo Maria} and Dragana Nikolic and Giglio, {Rosaria Vincenza} and Giuseppa Castellino and {Li Volti}, Giovanni and Massimiliano Caprio and Giuseppe Montalto and Vincenzo Provenzano and Stefano Genovese and Antonio Ceriello",
year = "2016",
month = "12",
day = "3",
doi = "10.1186/s12933-016-0480-8",
language = "English",
volume = "15",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome

T2 - An 18-month prospective study

AU - Rizzo, Manfredi

AU - Rizvi, Ali A.

AU - Patti, Angelo Maria

AU - Nikolic, Dragana

AU - Giglio, Rosaria Vincenza

AU - Castellino, Giuseppa

AU - Li Volti, Giovanni

AU - Caprio, Massimiliano

AU - Montalto, Giuseppe

AU - Provenzano, Vincenzo

AU - Genovese, Stefano

AU - Ceriello, Antonio

PY - 2016/12/3

Y1 - 2016/12/3

N2 - Background: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods: We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter. Results: There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months. Conclusions: Liraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.

AB - Background: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. Methods: We performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter. Results: There was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months. Conclusions: Liraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.

KW - Cardiovascular risk

KW - Carotid intima-media thickness

KW - Liraglutide

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85000981947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000981947&partnerID=8YFLogxK

U2 - 10.1186/s12933-016-0480-8

DO - 10.1186/s12933-016-0480-8

M3 - Article

AN - SCOPUS:85000981947

VL - 15

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

M1 - 162

ER -